Ischemic stroke has emerged as the leading cause of death and adult disability in China. Brozopentyl Sodium (BZP), an innovative agent for ischemic stroke, has been carefully developed by Zhejiang Ausun Pharmaceutical Co., Ltd (China). This first-in-human study explores BZP's safety, tolerability, and pharmacokinetic (PK) features in Chinese healthy volunteers. The results confirm that BZP is safe, well-tolerated, and shows predictable PK characteristics following single and multiple ascending intravenous infusion. These results support the further development potential of BZP for ischemic stroke patients.